Evidence map›Paper›PMID 39981706›Full record

ArticleImmunity, inflammation and disease2025

Changes of Peripheral T Cells in Systemic Lupus Erythematosus Patients.

Juanfeng Lao, Rongjun Huang, Rongcai Wu, Yulin Yuan

Abstract read
In one paragraph

Article in Immunity, inflammation and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Combined assessment of 25(OH)D, CD4Frontiers in immunology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Juanfeng LaoDepartment of Laboratory Medicine, Guangxi Academy of Medical Sciences, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China.ORCID 0000-0002-1996-6484
Rongjun HuangDepartment of Rheumatology and Immunology, Guangxi Academy of Medical Sciences, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China.
Rongcai WuDepartment of Laboratory Medicine, Guangxi Academy of Medical Sciences, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China.
Yulin YuanDepartment of Laboratory Medicine, Guangxi Academy of Medical Sciences, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China.ORCID 0000-0003-0393-7475

Funding

This study was supported by grants from the Foundation of National Natural Science Foundation of China (82460411), Guangxi Natural Science Foundation (2023GXNSFBA026104), Guangxi Zhuang Autonomous Region Health Committee Self-Financed Scientific Research Project (No. Z-A20220108), Guangxi Natural Science Foundation (2022GXNSFAA035498), and Guangxi Medical Health Appropriate Technology Research and Development Project (No. S2021047).
6 · The paper itself

Abstract

backgroundEfficient indicators for evaluating the imbalance of lymphocyte function were crucial to clinical therapy in systemic lupus erythematosus (SLE) patients. This study aimed to find biomarkers to assess lymphocyte-mediated immune response in SLE patients.

methodsA total of 81 SLE patients (non-active: n = 35, active: n = 46) and 70 healthy donors were recruited in the study. Peripheral blood was obtained, and flow cytometry was used to detect circulating lymphocytes.

resultsData showed that the counts of CD3

conclusionThis study indicated that monitoring the alterations of circulating lymphocyte counts and surface molecules may be helpful to assess disease activity of SLE patients, even discriminate active and non-active patients, which was beneficial to choose the best treatment option in clinical therapy.

Indexed as

Lupus Erythematosus, SystemicADP-ribosyl Cyclase 1AdultBiomarkersB-LymphocytesCD8-Positive T-LymphocytesFemaleFlow CytometryHLA-DR AntigensHumansKiller Cells, NaturalLymphocyte CountMaleMiddle AgedProgrammed Cell Death 1 ReceptorYoung AdultADP-ribosyl Cyclase 1BiomarkersHLA-DR AntigensProgrammed Cell Death 1 Receptoractivation moleculesinhibitory moleculeslymphocyteSLET cell

Identifiers

PMID39981706
PMCPMC11843224

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.